Education
About Us
Working with TipRanks
Follow Us
ImageneBio (IMA)
NASDAQ:IMA
IMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.64 - $23.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)34.42K
Market Cap
$158.22M
Enterprise Value-$25.30M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,181,676
10 Day Avg. Volume6,244
30 Day Avg. Volume34,416
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Merger BenefitsThe merger with Inmagene Biopharmaceuticals is expected to provide the combined company with an estimated $175 million in cash to support development of the anti-OX40 antibody, IMG-007.
Product PotentialIMG-007 has shown comparable efficacy to other OX40 therapies in development in atopic dermatitis, with a more favorable safety profile due to its non–T-cell-depleting design.
Bears Say
Shareholder ImpactFollowing the merger, current Ikena shareholders will own approximately 34.8% of the combined company, suggesting a combined company value of less than $300 million and enterprise value of below $120 million.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $11.64 and its highest was $23.28 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $158.22M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Overvalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,181,676 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.44%
12-Months-Change
Fundamentals
Return on Equity
-23.76%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
ImageneBio
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
ImageneBio (IMA) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Beyondspring
―
Adicet Bio
―
Precision BioSciences
―
MAIA Biotechnology, Inc.
―
Acrivon Therapeutics, Inc.
―